CA2667654C — Method of providing pirfenidone therapy to a patient
Assigned to Intermune Inc · Expires 2016-12-13 · 9y expired
What this patent protects
The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-l-phenyl-2-(lH)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated …
USPTO Abstract
The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-l-phenyl-2-(lH)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.